OnKure, Pfizer collaborate to evaluate combination of OKI-179 and binimetinib

This article was originally published here

Activating NRAS mutations occur in approximately 20% of melanomas, representing the second most common oncogenic driver mutation in melanoma after BRAF mutations. An unmet medical need remains for

The post OnKure, Pfizer collaborate to evaluate combination of OKI-179 and binimetinib appeared first on Pharmaceutical Business review.